{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-104564","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2024-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.788561+00:00","generated_at":"2026-05-31T05:56:16.870867+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SAB Bio completes Phase 1 healthy-volunteer enrollment; SAB-142 shows no serum sickness at 2.5 mg/kg","bullets":["Phase 1 trial of SAB-142 for type 1 diabetes completed all planned healthy-volunteer cohorts; no serum sickness observed at target 2.5 mg/kg dose.","Company now enrolling type 1 diabetes patients in the last cohort of the Phase 1 study.","Topline Phase 1 data readout expected by end of 2024.","SAB-142 is a first-in-class human anti-thymocyte immunoglobulin with differentiated safety profile compared to rabbit ATG."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-104564","json":"https://secwatch.observer/filing/0000950170-24-104564.json","markdown":"https://secwatch.observer/filing/0000950170-24-104564.md","text":"https://secwatch.observer/filing/0000950170-24-104564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024104564/0000950170-24-104564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024104564/sabs-20240909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:56:16.870867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}